Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes1

Heparin is one of the most effective drugs for preventing and treating thromboembolic complications in surgical patients. Recent evidence suggests that heparin enhances the proinflammatory responses of human peripheral blood monocytes to Gram-negative endotoxin (LPS). We have identified LPS-binding protein (LBP) as a novel heparin-binding plasma protein. The affinity of LPB to heparin was KD = 55 ± 8 nM, as measured by surface plasmon resonance. Using a fluorescence-based assay, we showed that clinically used heparin preparations significantly enhance the ability of LBP to catalytically disaggregate and transfer LPS to CD14, the LPS receptor. The presence of clinically relevant heparin concentrations in human whole blood increased LPS-induced production of the proinflammatory cytokine IL-8. Fondaparinux, which is identical with the antithrombin III-binding pentasaccharide in heparin, did not bind to LBP or alter LBP function. Thus, this novel anticoagulant drug is a potential candidate for safe administration to patients who have endotoxemia and require anticoagulation.

[1]  J. Hirsh,et al.  Heparin Binding Proteins Contribution to Heparin Rebound After Cardiopulmonary Bypass , 1993, Circulation.

[2]  J. Cavaillon,et al.  CD14/LPS receptor exhibits lectin-like properties , 1996 .

[3]  U. Göbel,et al.  Toll-like Receptor-2 Mediates Treponema Glycolipid and Lipoteichoic Acid-induced NF-κB Translocation* , 2001, The Journal of Biological Chemistry.

[4]  P. Balaram,et al.  Analysis of the binding of polymyxin B to endotoxic lipid A and core glycolipid using a fluorescent displacement probe. , 1992, Biochimica et biophysica acta.

[5]  W. Rom,et al.  Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF IL 6 and NF-kappa B. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[7]  J. Gegner,et al.  Lipopolysaccharide Binding Protein-mediated Complexation of Lipopolysaccharide with Soluble CD14 (*) , 1995, The Journal of Biological Chemistry.

[8]  R. Thieringer,et al.  Innate immune recognition of bacterial lipopolysaccharide: dependence on interactions with membrane lipids and endocytic movement. , 1998, Immunity.

[9]  D. Hardie.  Protein phosphorylation: a practical approach , 1993 .

[10]  S. Wright,et al.  Catalytic Properties of Lipopolysaccharide (LPS) Binding Protein , 1996, The Journal of Biological Chemistry.

[11]  U. Lindahl,et al.  Glycosaminoglycans and the regulation of blood coagulation. , 1993, The Biochemical journal.

[12]  P. Elsbach,et al.  Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. , 1992, The Journal of clinical investigation.

[13]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[14]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[15]  J. Wedemeyer,et al.  Roles of mast cells and basophils in innate and acquired immunity. , 2000, Current opinion in immunology.

[16]  W. Buurman,et al.  Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. , 1996, The Journal of infectious diseases.

[17]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[18]  D. Remick,et al.  Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model. , 1998, Shock.

[19]  N. Rao,et al.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Stephen F. Carroll,et al.  Dual Role of Lipopolysaccharide (LPS)-Binding Protein in Neutralization of LPS and Enhancement of LPS-Induced Activation of Mononuclear Cells , 2001, Infection and Immunity.

[21]  E. Abraham,et al.  Why immunomodulatory therapies have not worked in sepsis , 1999, Intensive Care Medicine.

[22]  S. Wright,et al.  Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide , 1986, The Journal of experimental medicine.

[23]  W. Rom,et al.  Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Heinzelmann,et al.  Heparin-binding protein (CAP37) is internalized in monocytes and increases LPS-induced monocyte activation. , 1998, Journal of immunology.

[25]  B. Persson,et al.  Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins , 1991 .

[26]  B. Monks,et al.  CD11/CD18 and CD14 share a common lipid A signaling pathway. , 1998, Journal of immunology.

[27]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[28]  M. Heinzelmann,et al.  Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. , 1999, Annals of surgery.

[29]  C. Bode,et al.  Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). , 1999, Circulation.

[30]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[31]  K. L. Miller,et al.  Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation. , 1994, The Journal of biological chemistry.

[32]  J. Kastrup,et al.  Two mutants of human heparin binding protein (CAP37): Toward the understanding of the nature of lipid A/LPS and BPTI binding , 2001, Proteins.

[33]  T. Bjornsson,et al.  Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. , 1988, The Journal of pharmacology and experimental therapeutics.

[34]  G. Skjåk‐Braek,et al.  The involvement of CD14 in stimulation of cytokine production by uronic acid polymers , 1993, European journal of immunology.

[35]  M. Heinzelmann,et al.  Arginine-Rich Cationic Polypeptides Amplify Lipopolysaccharide-Induced Monocyte Activation , 2002, Infection and Immunity.

[36]  B. Beutler,et al.  Tlr4: central component of the sole mammalian LPS sensor. , 2000, Current opinion in immunology.

[37]  S. Akira,et al.  CD11b/CD18 Acts in Concert with CD14 and Toll-Like Receptor (TLR) 4 to Elicit Full Lipopolysaccharide and Taxol-Inducible Gene Expression1 2 3 , 2001, The Journal of Immunology.

[38]  T. Abrahamsen,et al.  Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. , 1995, Thrombosis research.

[39]  E. Tuomanen,et al.  Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. , 2003, Immunity.

[40]  M. Krieger,et al.  Recognition and plasma clearance of endotoxin by scavenger receptors , 1991, Nature.

[41]  J. Bonifacino,et al.  The cytoplasmic domain mediates localization of furin to the trans- Golgi network en route to the endosomal/lysosomal system , 1994, The Journal of cell biology.

[42]  R. Tapping,et al.  Binding of Bacterial Peptidoglycan to CD14* , 1998, The Journal of Biological Chemistry.

[43]  H. Flad,et al.  Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes , 1997, Infection and immunity.

[44]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[45]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[46]  W. Mcbride,et al.  An investigation of the effects of heparin, low molecular weight heparin, protamine, and fentanyl on the balance of pro‐ and anti‐inflammatory cytokines in in‐vitro monocyte cultures , 1996, Anaesthesia.

[47]  J. Woody,et al.  In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. , 1996, Journal of immunology.

[48]  L. Kjellén,et al.  Proteoglycans: structures and interactions. , 1991, Annual review of biochemistry.

[49]  M. Heinzelmann,et al.  Fondaparinux sodium lacks immunomodulatory effects of heparin. , 2004, American journal of surgery.

[50]  Thomas Hartung,et al.  Cytokine induction by purified lipoteichoic acids from various bacterial species – Role of LBP, sCD14, CD14 and failure to induce IL‐12 and subsequent IFN‐γ release , 2002, European journal of immunology.